New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Monica A. Tincopa(University of California San Diego), Rohit Loomba(University of California San Diego), Quentin M. Anstee(Newcastle upon Tyne Hospital)
Cited by 100
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k